Analytical Data
-
Gene name
SF3B1
- Application
-
Alternative Names
SF3B1；SAP155；Splicing factor 3B subunit 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75533
-
Expression Region
326-571aa
-
AA Sequence
TPTPGASKRKSRWDETPASQMGGSTPVLTPGKTPIGTPAMNMATPTPGHIMSMTPEQLQAWRWEREIDERNRPLSDEELDAMFPEGYKVLPPPAGYVPIRTPARKLTATPTPLGGMTGFHMQTEDRTMKSVNDQPSGNLPFLKPDDIQYFDKLLVDVDESTLFPEEQKERKIMKLLLKIKNGTPPMRKAALRQITDKAREFGAGPLFNQILPLLMSPTLEDQERHLLVKVIDRILYKLDDLVRPYV
-
Molecular Weight
33.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SF3B1 (Splicing Factor 3b Subunit 1) is a crucial component of the spliceosome, a large RNA-protein complex responsible for the splicing of precursor mRNA into mature mRNA. Mutations in the SF3B1 gene have been linked to various hematological malignancies, notably myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These mutations lead to aberrant splicing events that can disrupt normal gene expression and contribute to cancer progression. The study of SF3B1 and its protein interactions is vital for understanding the molecular mechanisms underlying these diseases and may offer new therapeutic targets. Recombinant SF3B1 proteins have been utilized in biochemical assays to investigate their functional roles, interactions with other splicing factors, and effects on splicing regulation. Additionally, understanding the structural aspects of SF3B1 can facilitate the development of small molecules or inhibitors that can modulate its activity. As research progresses, elucidating the role of SF3B1 not only contributes to the understanding of cancer biology but also enhances prospects for novel treatment strategies that target splicing abnormalities in malignancies.
